Pharmacy teams are requested to support the safety study of the new Oxford / AstraZeneca COVID-19 vaccine to ensure that any side effects are quickly identified and acted upon.
The Southampton Department of Drug Safety Research (PSRS), an associate professor at the School of Pharmacy and Biomedical Sciences at the University of Portsmouth, now monitors vaccine safety by actively collecting near-real-time data from vaccine patients. ,
The DSRU will include at least 10,000 patients who will be contacted regularly after receiving the Oxford / AstraZeneca vaccine to see if they have any possible side effects. The study is a series of measures to promote public protection.
The DSRU recruits people from the UK as part of the entire Phase I vaccine group, which includes all people over the age of 50, health care professionals, and people who are clinically extremely vulnerable to COVID-19.
How can pharmacy teams help?
Pharmacy team members can register for the study themselves if they have had the Oxford / AZ vaccine.
In addition, pharmacy teams may encourage their patients who have received the Oxford / AZ vaccine to participate in the study.
People can register their interest before being vaccinated or register after receiving the Oxford / AstraZeneca vaccine here goto.dsru.org/covid: or by calling 0800 619 6222.
Download a poster to display at your pharmacy
Commenting on the start of the study: Professor Saad Shakir, Director of DSRU, he said.
“Doctors, nurses, pharmacists, health care providers, all other health professionals already understand the effects of COVID-19 on patients and their relatives, so we hope they will also understand how important it is for us to control new vaccines. և treatment to make them as safe and effective as possible.
“We urge all health professionals to gently encourage patients with the Oxford / AstraZeneca vaccine to register for our study. These are just a few short questionnaires for patients. But their contribution can play a huge role in our collective efforts to protect people from such a devastating disease. ”
Additional information about the study և DSRU
People can express their interest in participating in the vaccine before vaccination or registering within 28 days of receiving the vaccine. All participants will be required to have basic information about the vaccine and their health. After that, they will receive questionnaires with intervals of up to 18 months, which is provided by the study line. A random sample of participants will also be asked about their quality of life in the months following vaccination.
The DSRU research team will և review the information provided by participants to determine if any of the side effects observed in the study population are related to the vaccine. The team will provide monthly updates to the pharmaceutical manufacturer և Drug և Health Products Regulatory Authority. It will provide a summary of the study results on its website and will publish the results in scientific journals.
DSRU has gathered a consortium of doctors, pharmacists and scientists from 12 universities in the UK Միացյալ NHS trusts to assist with the study. The DSRU expects to conduct several active safety safety studies on the treatment of various COVID-19 vaccines, as they are approved for use in the general population.
DSRU is an independent, internationally recognized research unit that monitors, studies, transmits drug safety, and manages risk management.
For more information about DSRU, visit dsru.org.